These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24908540)

  • 1. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
    Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
    Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Amato RJ; Flaherty AL; Stepankiw M
    Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
    Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
    Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
    Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
    Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
    Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
    Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
    Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
    Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
    Albiges L; Kube U; Eymard JC; Schmidinger M; Bamias A; Kelkouli N; Mraz B; Florini S; Guderian G; Cattaneo A; Bergmann L
    Eur J Cancer; 2015 Nov; 51(16):2368-74. PubMed ID: 26276039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.